GC Biopharma Corp.
BiotechGC Biopharma Corp. is a biotechnology company focused on Infectious Disease.
GC Biopharma Corp. at a Glance
- Growing R&D activity with 4 trials in last 2 years
GC Biopharma Corp.'s Key Drugs
GC Biopharma Corp.'s core commercial portfolio centers on Alyglo, spanning Infectious Disease — its most strategically important drugs approved in the last 15 years.
GC Biopharma Corp.'s Recent FDA Approvals
New NDA/BLA approvals for GC Biopharma Corp. over the last two years — novel drugs only, excluding generics and label supplements.
GC Biopharma Corp.'s Therapeutic Areas
GC Biopharma Corp.'s approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GC Biopharma Corp.'s Top Competitors
GC Biopharma Corp.'s closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
GC Biopharma Corp. Pipeline Snapshot
GC Biopharma Corp. has 2 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 0 Phase 2 and 0 Phase 1.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Alyglo leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • 1 Phase 3 readout tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 1/4 completed
- • Speed: N/A months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2023-12-14
- Latest
- 2023-12-14
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges